# A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Study · id `cardio:ct-nct05182840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05182840](<https://clinicaltrials.gov/study/NCT05182840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05182840

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 714 participants.

## Technical summary

Registry record NCT05182840. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-11 (actual); primary completion 2023-06-19 (actual). Results posted on 2024-08-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 714 participants (enrolled count; ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Started: 2022-01-11 (actual) (ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Primary completion: 2023-06-19 (actual) (ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Completion: 2023-07-10 (actual) (ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Results first posted: 2024-08-29 (ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Finland; Germany; Greece; Hong Kong SAR China; Hungary; India; Italy; Japan; Malaysia; Mexico; Norway; Philippines; Poland; Portugal; South Africa; South Korea; Spain; Sweden; Switzerland; Türkiye (ClinicalTrials.gov record NCT05182840, source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05182840-2024-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
- Condition: Kidney Disease, Chronic
- Intervention (Drug): BI 690517
- Intervention (Drug): Placebo to BI 690517
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo to empagliflozin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial (`cardio:pubmed-38109916`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD (`cardio:pubmed-41436034`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses (`cardio:pubmed-42086479`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: aaa8db4c28840f8eb3339fefea890d7a948b2c646b4c859e4b348b5f013fc5d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
